Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc.
- Market cap
- $409
Your view on DRMAW
Overview
What the company does, where it operates, and who runs it.
About Dermata Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gerald T. Proehl
- Headquarters
- 3525 Del Mar Heights Road, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Gerald T. Proehl
- Headquarters
- 3525 Del Mar Heights Road, San Diego, CA, US
Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions.
Its flagship investigational product, DMT310, is a topical formula applied once weekly that is currently undergoing clinical trials. This primary compound is being evaluated for its effectiveness against acne vulgaris, psoriasis vulgaris, and papulopustular rosacea.
Additionally, the company is advancing DMT410, which is intended to address hyperhidrosis (excessive sweating) and other aesthetic concerns.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Dermata Therapeutics, Inc.. Starting points for Dermata Therapeutics, Inc.: EPS -$1476.80, beta 0.66 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Dermata Therapeutics, Inc.. Trailing twelve-month EPS for Dermata Therapeutics, Inc. stands at -$1476.80. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | −$0.56 | −$2.21 | −$1.52 |
| Low estimate | −$0.56 | −$2.21 | −$1.52 |
| High estimate | −$0.56 | −$2.21 | −$1.52 |
| No. of analysts | 1 | 1 | 1 |
| Year-ago EPS | −$1.52 | −$8.16 | — |
| Growth | +63.2% | +72.9% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|
| Avg. estimate | $75000.00 | $100000.00 | $750000.00 |
| Low estimate | $75000.00 | $100000.00 | $750000.00 |
| High estimate | $75000.00 | $100000.00 | $750000.00 |
| No. of analysts | 1 | 1 | 1 |
| Year-ago revenue | $0.00 | $0.00 | — |
| Growth | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Dermata Therapeutics, Inc.. Dermata Therapeutics, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AKTXAkari Therapeutics, Plc | Healthcare | Biotechnology | $15.3M | ||
| CDTCDT Equity Inc. | Healthcare | Biotechnology | $159,886 | ||
| FOXOFOXO Technologies Inc. | Healthcare | Medical - Care Facilities | $8,997 | ||
| PIIIP3 Health Partners Inc. | Healthcare | Medical - Care Facilities | $7.0M | ||
| PPBTPurple Biotech Ltd. | Healthcare | Biotechnology | $236,124 | ||
| REVBRevelation Biosciences, Inc. | Healthcare | Biotechnology | $2.2M | ||
| SLXNWSilexion Therapeutics Ltd. | Healthcare | Biotechnology | $42,542 | ||
| SYRSSyros Pharmaceuticals, Inc. | Healthcare | Biotechnology | $21,464 | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BCLIBrainstorm Cell Therapeutics Inc. | Healthcare | OTC | $6.8M | ||
| BCRXBioCryst Pharmaceuticals, Inc. | Healthcare | NASDAQ | $1.9B | ||
| BCT.TOBriaCell Therapeutics Corp. | Healthcare | TSX | $40.6M | ||
| BCTXBriaCell Therapeutics Corp. | Healthcare | NASDAQ | $28.6M | ||
| BCTXZBriaCell Therapeutics Corp. Warrant | Healthcare | NASDAQ | $239,235 | ||
| BCYCBicycle Therapeutics plc | Healthcare | NASDAQ | $218.0M | ||
| BDRXBiodexa Pharmaceuticals Plc | Healthcare | NASDAQ | $189,830 | ||
| BDTXBlack Diamond Therapeutics, Inc. | Healthcare | NASDAQ | $82.2M | ||
| BEAMBeam Therapeutics Inc. | Healthcare | NASDAQ | $2.2B | ||
| BETR.CNBetterLife Pharma Inc. | Healthcare | CNQ | — | ||
| BETRFBetterLife Pharma Inc. | Healthcare | OTC | $6.4M | ||
| BHVNBiohaven Ltd. | Healthcare | NYSE | $1.9B | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Dermata Therapeutics, Inc., and how their positions are changing. At a $409 market value, institutional positions materially move Dermata Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Dermata Therapeutics, Inc. executives and directors. Shares of Dermata Therapeutics, Inc. have traded between $0.0066 and $0.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Dermata Therapeutics, Inc.. Coverage tracks Dermata Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Dermata Therapeutics, Inc.